PD-L1 expressing triple-negative breast cancer

PD-L1–expressing triple-negative breast cancer is a biomarker-defined, aggressive subtype of breast carcinoma characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) overexpression or amplification Clinically quantified via companion immunohistochemical assays, this biomarker status identifies a distinct immunogenic tumor microenvironment associated with high invasiveness, elevated risk of early recurrence, and susceptibilit...

PD-L1–expressing triple-negative breast cancer is a biomarker-defined, aggressive subtype of breast carcinoma characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) overexpression or amplification It affects breast tissue—primarily presenting in adult female populations—and features prominent cellular expression of the immune checkpoint molecule programmed death-ligand 1 (PD-L1) on malignant cells, tumor-infiltrating lympho...

PD-L1–expressing triple-negative breast cancer is a biomarker-defined, aggressive subtype of breast carcinoma characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) overexpression or amplification

It affects breast tissue—primarily presenting in adult female populations—and features prominent cellular expression of the immune checkpoint molecule programmed death-ligand 1 (PD-L1) on malignant cells, tumor-infiltrating lymphocytes, or surrounding stromal histiocytes Pathophysiologically, tumor-associated PD-L1 binds to PD-1 receptors on cytotoxic T cells, promoting immune evasion and tumor proliferation through down-regulation of anti-tumor T-cell responses Clinically quantified via compani...

Pathophysiologically, tumor-associated PD-L1 binds to PD-1 receptors on cytotoxic T cells, promoting immune evasion and tumor proliferation through down-regulation of anti-tumor T-cell responses Clinically quantified via companion immunohistochemical assays, this biomarker status identifies a distinct immunogenic tumor microenvironment associated with high invasiveness, elevated risk of early recurrence, and susceptibility to immune checkpoint inhibition

Clinically quantified via companion immunohistochemical assays, this biomarker status identifies a distinct immunogenic tumor microenvironment associated with high invasiveness, elevated risk of early recurrence, and susceptibility to immune checkpoint inhibition